NeuBase Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
NeuBase Therapeutics, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$810.89 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2023-11-09
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-09-30 was -$810.89K.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-06-30 was -$1.43M.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-06-30 was -$215.55K, a 175.56% decline year-over-year.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-03-31 was -$90.60K.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2021 was -$950.15K, a 309.37% decline from fiscal 2020.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2020 was $453.81K, a 7.93% decline from fiscal 2019.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2019 was $492.89K.
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2012 was $3.31M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$810.89K 10-Q · filed 2023-11-09 | -$2.24M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2023-06-30 | -$1.43M 10-Q · filed 2023-11-09 | |||
| 2021-09-30 | -$950.15K 10-K · filed 2022-12-21 | |||
| 2021-06-30 | -$215.55K 10-Q · filed 2021-08-13 | -$306.14K derived: sum of 2 quarters · filed 2021-08-13 | -$936.26K derived: sum of 3 quarters · filed 2021-08-13 | |
| 2021-03-31 | -$90.60K 10-Q · filed 2021-08-13 | -$720.71K derived: sum of 2 quarters · filed 2021-08-13 | ||
| 2020-12-31 | -$630.11K 10-Q · filed 2021-08-13 | |||
| 2020-09-30 | $453.81K 10-K · filed 2021-12-23 | |||
| 2020-06-30 | $285.28K 10-Q · filed 2021-08-13 | $215.34K derived: sum of 2 quarters · filed 2021-08-13 | $909.47K derived: sum of 3 quarters · filed 2021-08-13 | |
| 2020-03-31 | -$69.94K 10-Q · filed 2021-08-13 | $624.19K derived: sum of 2 quarters · filed 2021-08-13 | ||
| 2019-12-31 | $694.13K 10-Q · filed 2021-08-13 | |||
| 2019-09-30 | $492.89K 10-K · filed 2020-12-23 | |||
| 2019-06-30 | $13.24K 10-Q · filed 2020-08-13 | $51.94K derived: sum of 2 quarters · filed 2020-08-13 | ||
| 2019-03-31 | $38.70K 10-Q · filed 2020-08-13 | |||
| 2013-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-13 | -$1.89M 10-Q · filed 2013-08-13 | ||
| 2013-03-31 | -$1.89M 10-Q · filed 2013-05-14 | |||
| 2012-09-30 | $3.31M 10-K · filed 2013-01-09 |